Regeneus Ltd (ASX:RGS)
Regeneus Ltd is an Australia-based, clinical-stage regenerative medicine company. The Company uses stem cell technologies to develop cell-based therapies. Its therapeutic areas include knee osteoarthritis, neuropathic pain and skin inflammation. The Company’s platform technologies consist of Progenza and Sygenus. The Progenza is a cellular therapy targeting pain and inflammation, which uses the secretome to improve Mesenchymal Signalling Cells (MSCs).The Progenza repairs local damaged tissue, such as cartilage tissue commonly found in joints like the knees and elbows. The Sygenus is a cell-free topical serum and gel treatment for pain and inflammation derived from Adipose MSCs. The Sygenus consists of selective bioactive molecules from the secretome. It reduces pain and inflammation, while accelerating tissue healing and repair.